Boehringer Ingelheim and Lilly's New Oral Type 2 Diabetes Treatment Available in U.S. Pharmacies

JENTADUETO is a new prescription medication for patients who need to control their blood sugar. The drug was approved by the FDA in January this year.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company have announced Jentadueto (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.

JENTADUETO is a new prescription medication for patients who need to control their blood sugar. Taken twice daily, it combines two diabetes medicines – the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin and metformin – in one tablet.

JENTADUETO was approved by the U.S. FDA on January 30, 2012, as a prescription medicine used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate.